110 related articles for article (PubMed ID: 21348862)
21. Curcumin is a direct inhibitor of glucose transport in adipocytes.
Green A; Krause J; Rumberger JM
Phytomedicine; 2014 Jan; 21(2):118-22. PubMed ID: 24060216
[TBL] [Abstract][Full Text] [Related]
22. ApoA-IV improves insulin sensitivity and glucose uptake in mouse adipocytes via PI3K-Akt Signaling.
Li X; Wang F; Xu M; Howles P; Tso P
Sci Rep; 2017 Jan; 7():41289. PubMed ID: 28117404
[TBL] [Abstract][Full Text] [Related]
23. Serine 474 phosphorylation is essential for maximal Akt2 kinase activity in adipocytes.
Kearney AL; Cooke KC; Norris DM; Zadoorian A; Krycer JR; Fazakerley DJ; Burchfield JG; James DE
J Biol Chem; 2019 Nov; 294(45):16729-16739. PubMed ID: 31548312
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
Simioni C; Neri LM; Tabellini G; Ricci F; Bressanin D; Chiarini F; Evangelisti C; Cani A; Tazzari PL; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Capitani S; Martelli AM
Leukemia; 2012 Nov; 26(11):2336-42. PubMed ID: 22614243
[TBL] [Abstract][Full Text] [Related]
25. Effects of erythropoietin on glucose metabolism.
Mikolás E; Cseh J; Pap M; Szijárto IA; Balogh A; Laczy B; Bekő V; Fisi V; Molnár GA; Mérei A; Szeberényi J; Wittmann I
Horm Metab Res; 2012 Apr; 44(4):279-85. PubMed ID: 22351476
[TBL] [Abstract][Full Text] [Related]
26. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
Yap TA; Yan L; Patnaik A; Fearen I; Olmos D; Papadopoulos K; Baird RD; Delgado L; Taylor A; Lupinacci L; Riisnaes R; Pope LL; Heaton SP; Thomas G; Garrett MD; Sullivan DM; de Bono JS; Tolcher AW
J Clin Oncol; 2011 Dec; 29(35):4688-95. PubMed ID: 22025163
[TBL] [Abstract][Full Text] [Related]
27. Oleic acid stimulates glucose uptake into adipocytes by enhancing insulin receptor signaling.
Tsuchiya A; Nagaya H; Kanno T; Nishizaki T
J Pharmacol Sci; 2014; 126(4):337-43. PubMed ID: 25391857
[TBL] [Abstract][Full Text] [Related]
28. Akt2-Dependent Beneficial Effect of Galanin on Insulin-Induced Glucose Uptake in Adipocytes of Diabetic Rats.
Zhang Z; Fang P; Guo L; He B; Shi M; Zhu Y; Bo P
Cell Physiol Biochem; 2017; 41(5):1777-1787. PubMed ID: 28365702
[TBL] [Abstract][Full Text] [Related]
29. YM201636, an inhibitor of retroviral budding and PIKfyve-catalyzed PtdIns(3,5)P2 synthesis, halts glucose entry by insulin in adipocytes.
Ikonomov OC; Sbrissa D; Shisheva A
Biochem Biophys Res Commun; 2009 May; 382(3):566-70. PubMed ID: 19289105
[TBL] [Abstract][Full Text] [Related]
30. Hyperinsulinemia leads to uncoupled insulin regulation of the GLUT4 glucose transporter and the FoxO1 transcription factor.
Gonzalez E; Flier E; Molle D; Accili D; McGraw TE
Proc Natl Acad Sci U S A; 2011 Jun; 108(25):10162-7. PubMed ID: 21646544
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
[TBL] [Abstract][Full Text] [Related]
32. In vitro selection of anti-Akt2 thioether-macrocyclic peptides leading to isoform-selective inhibitors.
Hayashi Y; Morimoto J; Suga H
ACS Chem Biol; 2012 Mar; 7(3):607-13. PubMed ID: 22273180
[TBL] [Abstract][Full Text] [Related]
33. Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors.
Seefeld MA; Rouse MB; McNulty KC; Sun L; Wang J; Yamashita DS; Luengo JI; Zhang S; Minthorn EA; Concha NO; Heerding DA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2244-8. PubMed ID: 19285393
[TBL] [Abstract][Full Text] [Related]
34. Dissecting the mechanism of insulin resistance using a novel heterodimerization strategy to activate Akt.
Ng Y; Ramm G; James DE
J Biol Chem; 2010 Feb; 285(8):5232-9. PubMed ID: 20022950
[TBL] [Abstract][Full Text] [Related]
35. [Ginsenoside Rb1 upregulates expressions of GLUTs to promote glucose consumption in adiopcytes].
Shang WB; Guo C; Zhao J; Yu XZ; Zhang H
Zhongguo Zhong Yao Za Zhi; 2014 Nov; 39(22):4448-52. PubMed ID: 25850283
[TBL] [Abstract][Full Text] [Related]
36. Effects of PKB/Akt inhibitors on insulin-stimulated lipogenesis and phosphorylation state of lipogenic enzymes in white adipose tissue.
Hussain N; Chuang SJ; Johanns M; Vertommen D; Steinberg GR; Kemp BE; Rider MH
Biochem J; 2020 Apr; 477(8):1373-1389. PubMed ID: 32215608
[TBL] [Abstract][Full Text] [Related]
37. An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.
Cherrin C; Haskell K; Howell B; Jones R; Leander K; Robinson R; Watkins A; Bilodeau M; Hoffman J; Sanderson P; Hartman G; Mahan E; Prueksaritanont T; Jiang G; She QB; Rosen N; Sepp-Lorenzino L; Defeo-Jones D; Huber HE
Cancer Biol Ther; 2010 Apr; 9(7):493-503. PubMed ID: 20139722
[TBL] [Abstract][Full Text] [Related]
38. Computational insights into the inhibitory mechanism of human AKT1 by an orally active inhibitor, MK-2206.
Rehan M; Beg MA; Parveen S; Damanhouri GA; Zaher GF
PLoS One; 2014; 9(10):e109705. PubMed ID: 25329478
[TBL] [Abstract][Full Text] [Related]
39. Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.
Gálvez-Peralta M; Flatten KS; Loegering DA; Peterson KL; Schneider PA; Erlichman C; Kaufmann SH
Mol Pharmacol; 2014 May; 85(5):723-34. PubMed ID: 24569089
[TBL] [Abstract][Full Text] [Related]
40. MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth.
Sefton EC; Qiang W; Serna V; Kurita T; Wei JJ; Chakravarti D; Kim JJ
Endocrinology; 2013 Nov; 154(11):4046-57. PubMed ID: 24002033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
